Florencia McAllister

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (22)

Supplementary figures and legends showing CAM effect on organ weight and blood chemistry analysis; survival study of CAM supplemented in chow diet; IHC staining of proliferation, apoptosis and angiogenesis; CAM treatment effect on lung microbiome.

Year:

2026

Drug repurposing is the process of reusing existing pharmaceuticals for novel clinical purposes, which offers advantages such as streamlined clinical trial access and reduced drug development costs. Clarithromycin (CAM), a member of the macrolide antibiotics family, is a promising candidate for repurposing in cancer therapy due to its known preclinical and clinical immunomodulatory and anticancer properties. In the current study, we investigated whether CAM could be repurposed as a preventive treatment for KRAS -mutant lung cancer, a subtype of lung adenocarcinoma that is strongly associated with heavy smoking. CCSP Cre ; LSL-Kras G12D mice at an early stage of tumor development were treated with different doses of CAM for 10 weeks. While exhibiting an excellent safety profile, CAM was able to prevent the development of premalignant and malignant lung lesions in a dose-dependent manner. In addition, CAM significantly reduced the infiltration of neutrophils/polymorphonuclear myeloid-derived suppressor cells and inhibited the mRNA expression of protumor inflammatory cytokines IL-6, TNFα, and IL-1β, as well as M2 macrophage markers Fizz1 and Arginase1 in the lung tumor microenvironment. Moreover, we investigated the effect of CAM in reshaping the intestinal and lung microbiome. Long-term CAM usage decreased intestinal microbiome diversity but, more notably, significantly increased the abundance of the probiotic genus Muribaculaceae while decreasing the abundance of Desulfovibrio , a genus associated with the promotion of various malignancies. Taken together, we conclude that CAM could provide promising cancer prevention efficacy in KRAS -mutant lung cancer due to its immunomodulatory properties on the tumor microenvironment and its regulatory effects on the microbiome.

Year:

2026

Introduction: nephron-sparing surgery (NSS) has emerged as the preferred treatment for renal tumors, aiming to balance oncological outcomes and renal function preservation. Partial nephrectomy (PN) has shown comparable cancer-specific survival rates to radical nephrectomy (RN). Notably, postoperative renal damage is associated with both ischemia time and parenchymal loss, emphasizing the importance of preserving renal function during tumor resection. The R.E.N.A.L. Nephrometry Score (RNS), has enhanced the quantification of renal tumor characteristics and improved standardization, guiding surgical decisions. This study aims to describe different hilum approaches based on RNS during laparoscopic PN and analyze their impact on surgical time, intraoperative bleeding, and functional outcomes. Methods: a retrospective analysis of 90 laparoscopic partial nephrectomy cases was conducted. Surgical time, estimated blood loss (EBL), renal hilum approach (including hilum dissection with renal artery clamping [HD&RAC], hilum dissection without renal artery clamping [HD&noRAC], and no hilum dissection with no renal artery clamping [noHD&noRAC), complication rates and RNS-guided complexity (low: RNS 9) were assessed. The choice of hilum approach and abdominal access was determined by the physician based on tumor complexity assessed using RNS. Results: surgical time varied significantly between hilum approaches, with HD&RAC being the longest (196min), followed by HD&noRAC (147min) and noHD&noRAC (130min). The mean surgical time was statistically significantly different between HD&RAC and HD&noRAC (p-value = 0.0005) and between HD&RAC and noHD&noRAC (p-value = 0.0001). Intraoperative bleeding was higher in the HD&RAC approach than the noHD&noRAC approach (p-value = 0.039). Pre- and post-surgery glomerular filtration rates did not significantly differ by hilum approach (p= 0.7255) or complexity of the renal mass (p= 0.5633). No intraoperative complications were reported. However, three patients with high RNS experienced postoperative urinary fistulas. Conclusion: the choice of renal hilum approach significantly impacts surgical time and intraoperative bleeding during laparoscopic partial nephrectomy. Using RNS to guide the approach selection allows for optimal surgical outcomes without compromising glomerular filtration rate (GFR). Further research is needed to validate these findings in larger, multicenter studies and assess long-term outcomes associated with different hilum approaches in laparoscopic PN.

Year:

2026

Dietary macronutrient composition has emerged as a key modulator of pancreatic tumorigenesis, yet the impact of lipid-rich diets, particularly ketogenic diets (KD) on the earliest stages of pancreatic cancer development remains unclear. To investigate how dietary lipids shape the initiation and progression of Kras-driven neoplasia, we examined the effects of low-fat diet (LFD), high-fat diet (HFD), and KD in the Ptf1a CreERT2 ;Kras G12V (Acinar KrasG12V ) mouse model. KD-fed mice showed the shortest survival (median 26 ± 7 days) compared with SD (87 ± 29; p = 0.02) and LFD (57 ± 27; p = 0.02), while HFD-fed mice also exhibited reduced survival relative to SD (35 ± 25; p = 0.05). KD feeding induced severe glucose intolerance and elevated circulating β-hydroxybutyrate levels. Histologically, KD-fed Acinar KrasG12V mice developed invasive, sarcomatoid-like pancreatic ductal adenocarcinoma (PDAC), while HFD-fed mice showed increased poorly differentiated PDAC; in both groups these aggressive tumors were associated with extensive fibrosis and increased stromal CD39 expression relative to tumor compartments. Proteomic analysis demonstrated activation of PI3K–Akt–mTOR and EGFR signaling in KD and HFD-fed Acinar KrasG12V mice. Serum cytokines/chemokines profiling revealed pro-inflammatory and pro-angiogenic milieu in KD-fed Acinar KrasG12V mice. Collectively, these results show that dietary lipid enrichment prior to oncogenic Kras activation may accelerate early pancreatic neoplasia and foster a microenvironment conducive to tumor progression. These findings underscore the need for careful consideration of KD use in individuals at elevated risk for pancreatic cancer.

Year:

2025

Table S6. Gene set enrichment analysis using the KEGG pathways and Gene Ontology Biological Processes databases. Pathways statistically significant activated or suppressed after twelve months exercise are displayed (BH-adjusted P-value

Year:

2025

Table S2. Number of Patients Experiencing Adverse Events by Maximum Grade consent and initiation of exercise regimen (Pre-Study) and in the exercise and usual care group. List with the number of patients experiencing adverse events. Should a patient experience any adverse event, the patient is counted only at the highest (maximum) grade experienced.

Year:

2025

Figure S5. (A) Gene Set Enrichment Analysis (GSEA) of BIOCARTA IL-6 pathway; (B) Gene set of IL-6-stimulated cell cultures; (C) Gene set in IL-6-deprived cell cultures. GSEA was performed by 1000 permutations. The maximum and minimum sizes for gene sets were 500 and 15, respectively. The y-axis represents the enrichment score (ES) and the x-axis lists the ranked genes by fold change. Vertical black lines on the x-axis represent the genes in gene sets. The green line connects points of ES and genes. ES is the maximum deviation from zero as calculated for each gene going down the ranked list and represents the degree of over-representation of a gene set at the top or the bottom of the ranked gene list. The P-value and ES are labeled at the top of the figure. The peak towards to left of the x-axis suggests a positive enrichment of the target gene set and vice versa.

Year:

2025

Table S3. Number of patients experiencing adverse events. Only those toxicities experienced while on the trial are presented in the table. Toxicities during the pre-study stage of the trial, for example, that were present before participants begin intervention were not included. Should a patient experience an adverse event more than once, the patient is only counted once at the highest grade for that adverse event.

Year:

2025

Table S1. Adverse events (AEs) experience by participants with possible or probable relation to the study intervention. Summary of the adverse events by grade, relationship, and arm. Adverse events were reported by subjects, including AEs that happened between consent and initiation of exercise regimen (Pre-Study) and in the exercise and usual care group.

Year:

2025

Figure S4. Relative change in prostaglandin metabolite levels after twelve months follow-up in usual care and exercise groups (A-C, Wilcoxon signed-rank test; ns, P>0.05; *, P ≤0.05; **, P≤0.01).

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (40)

Karen Basen-Engquist

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Dafna Bar-Sagi

NYU School of Medicine

UNITED STATES
View details

Daniel A. Laheru

Johns Hopkins University School of Medicine

UNITED STATES
View details

Kyle Poulsen

Assistant Professor

Michigan State University

UNITED STATES
View details

Parul Agarwal

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Holger Eltzschig

Professor and Chairman

McGovern Medical School at UTHealth

UNITED STATES
View details

Johannes Fahrmann

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Erika Yanil Faraoni

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Nirav Thosani

Division Director/Professor

The University of Texas Health Science Center at Houston

UNITED STATES
View details

Yisheng LI

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Susan C. Gilchrist

Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Alison Klein

Professor

-

UNITED STATES
View details

Samir M. Hanash

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

C. Marcelo Aldaz

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

James P. Allison

Professor and Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Eduardo Vilar

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Patrick Lynch

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Tingting Mills

Assistant Professor

The University of Texas Health Science Center at Houston

UNITED STATES
View details

Zhongming Zhao

Professor and Center Director

The University of Texas Health Science Center at Houston

UNITED STATES
View details

Jennifer A. Wargo

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Matthew H. G. Katz

Professor

-

UNITED STATES
View details

yulin dai

The University of Texas Health Science Center at Houston

UNITED STATES
View details

Ana De Jesus-Acosta

Johns Hopkins University

UNITED STATES
View details

curtis wray

Professor

The University of Texas Health Science Center at Houston

UNITED STATES
View details

Manoj Chelvanambi

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Thais Bartelli

Research Investigator

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Seyed Javad Moghaddam

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jennifer Bailey-Lundberg

Tenured Associate Professor

The University of Texas Health Science Center at Houston

UNITED STATES
View details

Ernest Hawk

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Michael P. Kim

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Alexander Lazar

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jessica Maxwell

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jin He

Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Humam Kadara

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Powel Brown

Professor and Chairman

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Christina Dieli-Conwright

Dana-Farber Cancer Institute

UNITED STATES
View details

Manu Sebastian

PROFESSOR

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

George Van Buren

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Guillermina Lozano

Professor and Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jay Kolls

Professor

Tulane University School of Medicine

UNITED STATES
View details